Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Paul A Vanderlaan, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Paul Vanderlaan and Kartik Sehgal.
Connection Strength

0.928
  1. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist. 2021 04; 26(4):281-287.
    View in: PubMed
    Score: 0.231
  2. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.226
  3. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 05; 22(3):e379-e389.
    View in: PubMed
    Score: 0.225
  4. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. J Thorac Oncol. 2019 01; 14(1):e1-e3.
    View in: PubMed
    Score: 0.197
  5. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 07; 13(7):1037-1042.
    View in: PubMed
    Score: 0.048
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.